Article Text

Download PDFPDF
Returning home sampling kits for STI and HIV testing in people using a digital health HIV-PrEP pathway (PrEP-EmERGE)
  1. Annie Russell1,
  2. Sarah Tasker1,
  3. Kayleigh Nichols1,
  4. Marc Tweed2,
  5. Mary Darking3,
  6. Jennifer Whetham1,
  7. Daniel Richardson1,4
  1. 1 Sexual Health & HIV medicine, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
  2. 2 Terrence Higgins Trust, Brighton, UK
  3. 3 School of Humanities and Social Science Care, Health and Emotional Wellbeing Research and Enterprise Group, University of Brighton, Brighton, UK
  4. 4 Brighton and Sussex Medical School, Brighton, UK
  1. Correspondence to Professor Daniel Richardson, Sexual Health & HIV, University Hospitals Sussex NHS Foundation Trust, Brighton BN2 5BE, UK; daniel.richardson7{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Current standard of care for people using oral HIV-pre-exposure prophylaxis (PrEP) involves face-to-face clinic appointments for HIV, syphilis, gonorrhoea and chlamydia (STI) testing every 3 months.1 Providing more convenient clinical pathways can help optimise HIV-PrEP as a prevention strategy.2 PrEP-EmERGE is an mHealth application (app) and digital pathway co-designed by users and clinicians to support and empower people using HIV-PrEP, and reduce the number of face-to-face clinic appointments.3 PrEP-EmERGE aims to support people using HIV-PrEP by providing users with secure access to their results (recent and historic), a diary function with medication reminders, vaccination history, details of upcoming appointments and a messaging system which facilitates communication from the clinic to the end user.3 We invite existing HIV-PrEP users who use a personal smartphone, do not require interventions for drug/alcohol dependence, have not previously had syphilis, and have completed hepatitis A, hepatitis B and human papilloma virus vaccinations to use PrEP-EmERGE. Starting in August 2021, as part of each …

View Full Text


  • Handling editor Anna Maria Geretti

  • Contributors DR designed this study; AR and ST collected the data; AR analysed the data; and AR, ST, KN, MT, MD, JW and DR all contributed to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.